Thrivent Financial for Lutherans Has $153.31 Million Position in Masimo Co. (NASDAQ:MASI)

Thrivent Financial for Lutherans boosted its position in shares of Masimo Co. (NASDAQ:MASI) by 42.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,217,357 shares of the medical equipment provider’s stock after purchasing an additional 360,497 shares during the quarter. Thrivent Financial for Lutherans owned 2.29% of Masimo worth $153,314,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MASI. Bamco Inc. NY acquired a new position in Masimo during the first quarter valued at approximately $50,781,000. Schroder Investment Management Group lifted its stake in Masimo by 59.6% in the fourth quarter. Schroder Investment Management Group now owns 877,539 shares of the medical equipment provider’s stock valued at $102,856,000 after buying an additional 327,863 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in Masimo by 35.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 818,476 shares of the medical equipment provider’s stock valued at $95,934,000 after buying an additional 214,795 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Masimo by 13.6% in the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock valued at $218,742,000 after buying an additional 177,914 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Masimo by 45.9% in the second quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock valued at $66,201,000 after buying an additional 165,257 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Performance

Shares of MASI stock opened at $121.42 on Friday. The company’s fifty day simple moving average is $115.01 and its 200-day simple moving average is $125.04. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The firm has a market cap of $6.46 billion, a PE ratio of 82.60 and a beta of 0.98. Masimo Co. has a 12 month low of $75.22 and a 12 month high of $153.93.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business had revenue of $496.30 million for the quarter, compared to analyst estimates of $493.92 million. During the same quarter in the previous year, the firm posted $0.62 earnings per share. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. Equities research analysts expect that Masimo Co. will post 3.87 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on MASI. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Friday. Piper Sandler lifted their price target on shares of Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $144.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.